Hundreds more people with suspected kidney cancer should have a biopsy to help confirm their diagnosis sooner and treat their disease more effectively, according to new draft guidelines from NICE.

Durvalumab, also known as Imfinzi and made by AstraZeneca, is recommended in final draft guidance for adults with limited-stage small cell lung cancer (SCLC). This is where the cancer is contained in ...

In the lead-up to World Duchenne Awareness Day on Sunday 7 September, we’re pleased to announce the completion of our first assessment of an externally developed clinical guideline.

Fertility clinics should not offer unproven treatments that don't help people have babies, our independent committee has recommended in draft guidance.

There are commercial access agreements for enfortumab vedotin and pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Pneumonia: diagnosis and management QS110 19 January 2016 2 September 2025 Pneumonia: diagnosis and management NG250 2 September 2025 2 September 2025 Suspected acute respiratory infection in over 16s ...

This guidance has been updated and replaced by NICE technology appraisal guidance TA798 ...

This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic ...

NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We ...

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults. There is a commercial access agreement ...

This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z‑drugs and antidepressants in primary and secondary care. It does not ...